Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CHIMERIX INC (CMRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Investor presentation, Quarterly results
Docs: "Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update – Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries&#59; Reiterate First Interim Overall Survival Analysis Expected Early 2025 –",
"Chimerix Corporate Presentation August 3, 2023 2 Forward-Looking Statements This"
06/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Investor presentation, Quarterly results
Docs: "Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update – Continued Execution and Progress Towards Commercial Approval of Dordaviprone with Global Launch of Phase 3 ACTION Study –",
"2 Forward-Looking Statements This"
01/12/2023 8-K Investor presentation
Docs: "Annual J.P. Morgan Healthcare Conference January 12, 2023"
12/09/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/31/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
08/08/2022 8-K Quarterly results
08/01/2022 8-K Other Events  Interactive Data
06/28/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
04/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Chimerix, Inc.Officer Severance Benefit Plan"
04/13/2022 8-K Regulation FD Disclosure  Interactive Data
03/01/2022 8-K Quarterly results
01/31/2022 8-K Quarterly results
12/23/2021 8-K Other Events  Interactive Data
11/22/2021 8-K Investor presentation
11/04/2021 8-K Quarterly results
Docs: "Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update – Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma –",
"Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma – Blinded Independent Central Review of ONC201 Cohort Reported 20.0% Objective Response Rate by RANO-HGG Criteria –"
08/05/2021 8-K Quarterly results
Docs: "Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update – Received U.S. Food and Drug Administration Approval for TEMBEXA® for the Treatment of Smallpox –"
06/25/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
01/21/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "11,765,000 Shares CHIMERIX, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT",
"2505 Meridian Parkway, Suite 100"
01/13/2021 8-K Quarterly results
01/08/2021 8-K Quarterly results
12/23/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment to the Supply Agreement"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy